• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Longeveron Inc.

    7/23/24 1:41:35 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001721484
    LONGEVERON LLC
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Longeveron Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Longeveron Inc.
    Street Address 1 Street Address 2
    1951 NW 7TH AVENUE SUITE 520
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    MIAMI FLORIDA 33136 305-909-0840

    3. Related Persons

    Last Name First Name Middle Name
    Hashad Wa'el
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hare Joshua M.
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Locklear Lisa A.
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 530
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Agafonova Nataliya
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Lehr Paul
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hare Neil E.
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Soffer Rock
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ungaro Ursula
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Baluch Khoso
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kender Richard
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Motwani Neha J.
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hajjar Roger Joseph
    Street Address 1 Street Address 2
    1951 NW 7TH Avenue Suite 520
    City State/Province/Country ZIP/PostalCode
    Miami FLORIDA 33136
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-07-19    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    H.C. Wainwright & Co., LLC 375
    (Associated) Broker or Dealer    None
    (Associated) Broker or Dealer CRD Number    None
    Craig Schwabe 3137679
    Street Address 1 Street Address 2
    430 Park Avenue 4TH Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW YORK

    Recipient
    Recipient CRD Number    None
    H.C. Wainwright & Co., LLC 375
    (Associated) Broker or Dealer    None
    (Associated) Broker or Dealer CRD Number    None
    Charles Worthman 5160596
    Street Address 1 Street Address 2
    430 Park Avenue 4TH Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW YORK

    Recipient
    Recipient CRD Number    None
    H.C. Wainwright & Co., LLC 375
    (Associated) Broker or Dealer    None
    (Associated) Broker or Dealer CRD Number    None
    Michael Vasinkevich 2843810
    Street Address 1 Street Address 2
    430 Park Avenue 4TH Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW YORK

    Recipient
    Recipient CRD Number    None
    H.C. Wainwright & Co., LLC 375
    (Associated) Broker or Dealer    None
    (Associated) Broker or Dealer CRD Number    None
    Noam Rubinstein 4070245
    Street Address 1 Street Address 2
    430 Park Avenue 4TH Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10022
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $9,508,010 USD
    or    Indefinite
    Total Amount Sold $0 USD
    Total Remaining to be Sold $9,508,010 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    The total offering amount reflects the purchase price of warrants and the exercise price due to the Company assuming cash exercise of all warrants issued to the accredited investors and placement agent in the private placement under Rule 506(b).

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    3

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $630,000 USD
    X Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    In connection with the registered direct offering, the placement agent received $630,000.33, and warrants to purchase up to 156,522 shares of Common Stock exercisable at $5.0313 per share, among other items.

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Longeveron Inc. /s/ Wa'el Hashad Wa'el Hashad Chief Executive Officer 2024-07-23

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $LGVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/12/24 7:00:29 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Locklear Lisa covered exercise/tax liability with 10,250 shares, decreasing direct ownership by 4% to 228,831 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    1/6/26 6:00:19 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agafonova Nataliya covered exercise/tax liability with 10,250 shares, decreasing direct ownership by 5% to 216,564 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    1/6/26 6:00:23 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel, Secretary Lehr Paul T covered exercise/tax liability with 6,952 shares, decreasing direct ownership by 2% to 344,177 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    1/6/26 6:00:21 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program

    The Mikaela Naylon Give Kids a Chance Act reauthorizes the Pediatric Priority Review Voucher (PPRV) Program and extends eligibility for medicines achieving U.S. FDA approval before September 2029The Pediatric Priority Review Voucher program encourages the development of treatments for rare pediatric diseasesU.S. FDA has awarded Longeveron's laromestrocel Hypoplastic Left Heart Syndrome (HLHS) program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationWith the extension of the PPRV Program, Longeveron may be granted a Priority Review Voucher if laromestrocel's Biological License Application (BLA) is approved by the FDA before September 2029 MIAMI, Feb. 05

    2/5/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)

    The patent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord or a placenta or differentiated from induced pluripotent stem cells (IPSCs)Patent issuance contributes to Longeveron's growing international patent portfolio protecting its clinical programs and productsLaromestrocel, Longeveron's proprietary mesenchymal stem cell therapy, has delivered positive initial results across five clinical trials in three indications, including Hypoplastic Left Heart Syndrome, Alzheimer's disease and Aging-related Frailty MIAMI,

    1/29/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

    ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designationLaromestrocel HLHS program has the potential to address an unmet medical need with significant U.S. market opportunitiesEven with current standard of care surgeries, only 50% of infants survive to adolescence due to right ventricular failure MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnol

    1/26/26 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    SEC Filings

    View All

    Longeveron Inc. filed SEC Form 8-K: Leadership Update

    8-K - Longeveron Inc. (0001721484) (Filer)

    11/12/25 6:20:54 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Longeveron Inc. (0001721484) (Filer)

    11/4/25 4:15:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Longeveron Inc.

    10-Q - Longeveron Inc. (0001721484) (Filer)

    11/4/25 4:00:55 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ROTH MKM initiated coverage on Longeveron with a new price target

    ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

    12/6/24 7:54:21 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EF Hutton initiated coverage on Longeveron with a new price target

    EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

    1/5/22 10:22:40 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    View All

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Than Powell as Chief Business Officer

    Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

    6/26/25 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

    MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

    11/11/24 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Financials

    Live finance-specific insights

    View All

    Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

    MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:   Conference Call Number: 1.877.407.0789Conference ID: 13755997   Call me™ Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available on the "Events & Presenta

    10/28/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

    MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:  Conference Call Number:1.877.407.0789Conference ID:13754295  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on t

    8/5/25 9:15:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

    Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

    5/8/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

    SC 13G/A - Longeveron Inc. (0001721484) (Subject)

    11/14/24 4:20:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    7/26/24 4:18:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Longeveron Inc.

    SC 13G - Longeveron Inc. (0001721484) (Subject)

    4/17/24 4:03:33 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care